Nasopharyngeal cancer
Conditions
Interventions
Large-fraction radiotherapy group:Hypofractionated radiotherapy dose of 2.64Gy/time, 5 times/week, for a total of 25 doses, with a total of 66Gy/5 weeks, was administered to patients with nasopharynge
Sponsors
The Second Affiliated Hospital of Hainan Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. ECOG score 0-2; 2. Age 18-75 years, male or non-pregnant female; 3. Pathologic diagnosis of nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated, regardless of TNM stage); 4. Have at least one evaluable lesion (according to RECIST1.1 criteria); 5. Expected survival time>=6 months; 6. The functional level of major organs meets the following criteria: (1) hematology: WBC>=3.0×109/L, ANC>=1.5×10^9/L, PLT >=100×10^9/L, HGB>=90g/L; (2) Liver function: ALT, AST=60ml/min (Cockcroft-Gault formula); (4) Good coagulation function: defined as international normalized ratio (INR) or prothrombin time (PT) <=1.5 times ULN; (5) Cardiac enzyme spectrum within the normal range; 7. The patient has signed the informed notice and is willing and able to comply with the visits, treatment plans, and laboratory tests of the study plan.
Exclusion criteria
Exclusion criteria: 1. Severe comorbidities judged by the investigator to be intolerant or complete radiotherapy; 2. There are contraindications to magnetic resonance examination; 3. Presence of acute inflammation requiring systemic therapy; 4. In the active period of infectious diseases; 5. Pregnant women, lactating women, and patients with birth plans during the study; 6. Participation in other clinical trials currently or within 4 weeks prior to enrollment; 7. Inability to comply with the study protocol and follow-up procedures; 8. Any other disease, metabolic disorder, physical examination findings, or abnormal laboratory test results as judged by the investigator and with reasonable suspicion of diseases or conditions that may cause contraindications to the use of the study treatment regimen, or affect the reliability of the study results, or put the patient at high risk of treatment complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Countries
China
Contacts
Public ContactYuecan Zeng
The Second Affiliated Hospital of Hainan Medical University
Outcome results
None listed